Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (1909)	3/6/2008 10:55:32 AM
From: Jibacoa	Respond to of 3722

CBTE Is up 7.92% on low volume of 695 about 0.01x its ADV.<g> bigcharts.marketwatch.com It reported that the US Patent Office issued it a patent for Real Time PCR Analysis of the different HHVs. CBTE had been performing the assays detailed in the patent for the 7 Yrs for physicians and clinics & now that it is patent protected, the technology will be offered to third party licensees. It will share with Vigen, a private company,any licensing and royalty from licensee. Of the 8 known HHVs, the alpha HVs include the HSV 1, HSV 2, & the varicellovirus, HHV 3. The beta HVs include cytomegalovirus (HHV 5), HHV 6, & the rosolovirus, HHV 7. The gamma HVs include the Epstein Barr, HHV 4 & Rhadinovirus, HHV 8. The EBV is the most prevalent & it is estimated that more than 90% of the world’s population is infected with it. Besides its association with infectious mononucleosis, it is also implicated in oncogenesis, particularly in relation to Burkitt’s lymphoma nasopharyngeocarcinoma. Infection also is associated with immuno-suppressed patients and with patients suffering from Hodgkin’s disease. CBI’s assay platform provides rapid and specific assay of each of the various HHVs in blood serum, sputum & cerebrospinal fluid. The CBI group operates 4 business units: (1) CBI Services, an early entry contract research organization, (2) Fairfax Identity Laboratories, a DNA reference lab; (3) Mimotopes Pty, of Melbourne, Australia, a peptide and discovery chemistry business; & (4) Tripos Discovery Research,of Bude, England, a medicinal and synthetic discovery chemistry business. The insiders reportedly hold about 50% of the stock & the float is < 3M. It seems to have support at the $2 level & although it has considerable resistance at the $2.50 level, under a better market environment it seems to have a chance to get to the $4 level.<g> bigcharts.marketwatch.com Bernard